RE:RE:Initial Takegudisgood wrote: Some additional thoughts:
- Although this is an obviously biased thought, there’s a chance the guidance is very conservative, but it could be the “real” estimate as well, it’s hard to say. But I believe the GUD management really doesn’t want to publish a downwards revised guidance for the year. One reason for the seemingly low growth could be that the growth was unusually high during 2021 due to the special demand caused by covid. On the other hand, the “normal” situation as far as the effect of the sales team getting out there and the treatments and so forth returns more slowly.
If we adjust 2021 revenue by $16M of covid-19 infectious diseases sales, we get $227M of adjusted revenue for 2021 (14% increase to 2020). Compared to that, the 2022 guidance of $265M is a 16% increase. Obviously this is not a great comparison because of several factors/reasons... but perhaps partly explains the fairly low revenue growth guidance in relation to 2021.
From the annual information form: "In 2021, Knight recorded approximately $13,500 to $16,300 of revenues related to a higher demand for our infectious diseases to treat invasive fungal infections associated with Covid-19. Such sales may not continue into 2022."